Company: BGLC
Filing Date: 2025-04-29
Form Type: 10-K/A
Source: 0001477932-25-003062
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-29
Form: 10-K/A
Chunk 2
---
 value of the registrant’s common stock held by non-affiliates of the registrant was approximately $ million (this amount represents approximately 17.2 million shares of BioNexus Gene Lab Corp’s common stock based on the last reported sales price of $0.4752 of the common stock on such date).

As of December 31, 2024, there were shares of common stock, no par value, outstanding.

<div align='center'>Explanatory Note</div>

BioNexus Gene Lab Corp. (the "Company," "we," "our," or "us") is filing this Amendment No. 1 ("Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, originally filed with the Securities and Exchange Commission (the "SEC") on April 15, 2025 (the "Original Filing"), to amend Item 15 of Part IV solely to file as an exhibit the Company's Policy on Recovery of Erroneously Awarded Compensation ("Clawback Policy") adopted to comply with Rule 10D-1 under the Securities Exchange Act of 1934 and Nasdaq Listing Rule 5608.

The Clawback Policy is attached hereto as Exhibit 97. No other changes are being made to the Original Filing. This Amendment No. 1 does not reflect events occurring after the filing date of the Original Filing and does not modify or update any disclosures made in the Original Filing except as described above.

| 2 |

Item 6. Exhibits.

| Exhibit |     | Description                                                                                                                                                                                            |
| 97      |     | Policy Relating to Recovery of Erroneously Awarded Compensation*                                                                                                                                       |
| 31.1    |     | Certification of the Company’s Principal Executive Officer  and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* |
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL Document)*                                                                                                                           |

* Filed Herewith

| 3 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| BIONEXUS GENE LAB CORPORATION                                                     |
| /s/ Su-L